journal
MENU ▼
Read by QxMD icon Read
search

Oncology (Williston Park, NY)

journal
https://www.readbyqxmd.com/read/28299760/uterine-sarcomas-the-latest-approaches-for-these-rare-but-potentially-deadly-tumors
#1
REVIEW
Jing-Yi Chern, Leslie R Boyd, Stephanie V Blank
Uterine sarcomas are rare malignant uterine neoplasms that are responsible for a large majority of uterine cancer-associated deaths. The subtypes include leiomyosarcomas, endometrial stromal tumors, and adenosarcomas. Standard treatment includes complete surgical resection. Adjuvant treatment with chemotherapy, hormonal therapy, or radiation may be considered in patients with high-risk disease. However, because the ability of adjuvant treatment to improve overall survival in patients with uterine sarcomas is unclear, there is no standard recommendation regarding adjuvant therapy...
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299759/optimizing-the-benefit-of-cns-radiation-therapy-in-the-pediatric-population-part-2-novel-methods-of-radiation-delivery
#2
REVIEW
Lindsay S Rowe, Andra V Krauze, Holly Ning, Kevin A Camphausen, Aradhana Kaushal
Newer approaches in the field of radiation therapy have raised the bar in the treatment of central nervous system (CNS) malignancies, with recognized advances that have aimed to increase the therapeutic index by improving conformality of the radiation dose to the planned target volume. Beyond these advances, the continued evolution of more effective systems for delivery of radiation to the CNS may offer further benefit not only to adults but also to pediatric patients, a cohort of the population that may be more sensitive to the long-term effects of radiation...
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299758/seventy-year-old-man-with-large-bladder-mass-diagnostic-and-clinical-challenges-of-an-uncommon-neoplasm
#3
Tamara P Lhungay, Alexandra Colvin, Jason Warncke, Hilary Somerset, Shandra S Wilson, Francisco G La Rosa
No abstract text is available yet for this article.
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299757/nanoparticle-delivered-chemotherapy-old-drugs-in-new-packages
#4
REVIEW
Michael S Lee, E Claire Dees, Andrew Z Wang
Cytotoxic chemotherapies have a narrow therapeutic window, with high peaks and troughs of plasma concentration. Novel nanoparticle formulations of cytotoxic chemotherapy drugs can enhance pharmacokinetic characteristics and facilitate passive targeting of drugs to tumors via the enhanced permeability and retention effect, thus mitigating toxicity. Nanoparticle vehicles currently in clinical use or undergoing clinical investigation for anticancer therapies include liposomes, polymeric micelles, protein-drug nanoparticles, and dendrimers...
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299756/counterpoint-standard-vs-investigational-agents-as-upfront-treatment-for-high-risk-aml
#5
Andrew M Brunner, Wendy Stock
No abstract text is available yet for this article.
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299755/point-standard-vs-investigational-agents-as-upfront-treatment-for-high-risk-aml
#6
Charles A Schiffer
No abstract text is available yet for this article.
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299754/optimizing-the-benefit-of-cns-radiation-therapy-in-the-pediatric-population-part-1-understanding-and-managing-acute-and-late-toxicities
#7
REVIEW
Lindsay S Rowe, Andra V Krauze, Holly Ning, Kevin A Camphausen, Aradhana Kaushal
Radiation therapy continues to be a key component in the management of pediatric malignancies. Increasing the likelihood of cure while minimizing late treatment toxicity in these young patients remains the primary goal. Within the realm of central nervous system neoplasms, efforts to further improve the efficacy of radiation therapy continue, while balancing risks of damage to uninvolved tissue. Radiation therapy can result in second malignancies, as well as cerebrovascular, neurotoxic, neurocognitive, endocrine, psychosocial, and quality-of-life effects...
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299753/pubic-bone-osteomyelitis-and-pubosymphyseal-urinary-fistula-a-poorly-recognized-complication-in-prostate-cancer-survivors
#8
Ramiro Jose Madden-Fuentes, Andrew C Peterson
No abstract text is available yet for this article.
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299752/therapeutic-implications-of-molecular-subtyping-for-pancreatic-cancer
#9
REVIEW
Michael J Pishvaian, Jonathan R Brody
The prognosis of metastatic pancreatic adenocarcinoma has recently begun to improve. In the last several years, first-line therapy with gemcitabine plus nab-paclitaxel or a regimen of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has boosted the median overall survival (OS) duration to 8.5 months and 11 months, respectively, in patients with metastatic pancreatic cancer, compared with a historic OS of only 6 months prior to 2011. Moreover, sequencing these two regimens improved median OS to an unprecedented 18 months...
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299751/maurie-markman-on-the-groundbreaking-tapur-trial
#10
Maurie Markman
No abstract text is available yet for this article.
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28205194/novel-and-expanded-oncology-drug-approvals-of-2016-part-2-new-options-in-the-management-of-hematologic-malignancies
#11
REVIEW
Todd C Knepper, James Saller, Christine M Walko
The recent past has brought pharmacotherapeutic advances that benefit patients with hematologic malignancies. In 2016, two novel hematology drugs were approved and four previously approved hematology drugs were granted expanded use for the treatment of appropriate patient populations by the US Food and Drug Administration. These new approvals and indications represent significant steps forward in patient management: they include the first-in-class B-cell lymphoma 2 inhibitor, venetoclax, the newest targeted therapy available for the treatment of hematologic malignancies; and nivolumab, the first immune checkpoint inhibitor to be approved for treatment of a hematologic malignancy...
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28205193/new-therapeutic-strategies-for-triple-negative-breast-cancer
#12
REVIEW
Borbála Székely, Andrea L M Silber, Lajos Pusztai
Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer (TNBC) since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options such as immune checkpoint inhibitors and antibody-drug conjugates. Evidence also increasingly supports that platinum drugs and inhibitors of poly (ADP-ribose) polymerase, or PARP, are particularly effective in the treatment of germline BRCA-mutant cancers, including TNBC...
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28205192/a-60-year-old-man-with-progressive-anemia-while-receiving-checkpoint-blockade-therapy-for-relapsed-myelofibrosis
#13
Aaron M Goodman, Megan Rust, Caitlin Costello, Edward D Ball
No abstract text is available yet for this article.
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28205191/novel-and-expanded-oncology-drug-approvals-of-2016-part-1-new-options-in-solid-tumor-management
#14
REVIEW
Todd C Knepper, James Saller, Christine M Walko
The nonradiologic medical management of solid tumors has evolved from the use of traditional cytotoxic agents to modern targeted therapies, monoclonal antibodies, and immunotherapies. Advances in the understanding of cancer biology and therapeutic strategies have resulted in increasing numbers of new drug applications and approvals. Consequently, practicing oncologists need to learn how the newly available agents function and what toxicities to watch for, as well as ways to optimize the use of both new drugs and previously approved drugs with new indications...
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28205190/accelerated-partial-breast-irradiation-for-breast-cancer-not-ready-for-routine-use
#15
Jacqueline R Kelly, Suzanne Evans
No abstract text is available yet for this article.
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28205189/accelerated-partial-breast-irradiation-for-breast-cancer-an-innovative-option-for-selected-early-stage-cancers
#16
Robert R Kuske
No abstract text is available yet for this article.
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28205188/understanding-the-links-between-lung-cancer-copd-and-emphysema-a-key-to-more-effective-treatment-and-screening
#17
REVIEW
Luis M Seijo, Javier J Zulueta
Lung cancer has been linked to the changes in lung function characteristic of chronic obstructive pulmonary disease (COPD) and to the changes in lung morphology seen in emphysema. It seems that a common thread of smoking-induced lung injury can be traced to all three diseases. However, the association is not as straightforward as it may seem; for example, even never-smokers with emphysema have an increased risk of lung cancer. Whether lung cancer, COPD, and emphysema are linked by common genes, mechanisms, causes, or a combination thereof, understanding the associations between them has become a priority for research regarding tobacco-related illnesses...
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28205187/barbara-mcaneny-on-how-the-repeal-of-the-aca-without-a-replacement-threatens-the-health-of-patients-and-the-success-of-community-practices
#18
Barbara L McAneny
No abstract text is available yet for this article.
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28090627/fdg-pet-for-early-response-assessment-in-lymphomas-part-2-diffuse-large-b-cell-lymphoma-use-of-quantitative-pet-evaluation
#19
REVIEW
Bruce D Cheson, Lale Kostakoglu
In Part 1, we reviewed the role of interim positron emission tomography (PET)/CT scans in Hodgkin lymphoma. In advanced Hodgkin lymphoma, interim PET is a useful prognostic tool that can be used to implement risk-adapted therapy with potential benefits for both patients who have negative interim scans and those whose scans are positive. Interim PET/CT has not shown as encouraging results in diffuse large B-cell lymphoma (DLBCL), with the exception of germinal center B-cell DLBCL. Thus, quantitative methods of interpreting interim PET scans have been pursued in an effort to improve their predictive value...
January 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28090626/active-surveillance-of-prostate-cancer
#20
Peter L Choyke, Stacy Loeb
No abstract text is available yet for this article.
January 15, 2017: Oncology (Williston Park, NY)
journal
journal
29689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"